Bio-Techne Corporation (TECH) Carries Attractive FY27 Organic Growth Projections

Bio-Techne Corporation (NASDAQ:TECH) is one of the 10 best life sciences stocks to buy according to hedge funds.

On February 5, Daniel Arias from Stifel Nicolaus reaffirmed his Hold rating on Bio-Techne Corporation (NASDAQ:TECH). He raised the stock’s price target from $60 to $65, implying a double-digit upside potential of 13%.

Arias noted that despite the company’s second-quarter beat, there are expectations of flat mid-year growth. He also anticipates an unchanged forecast for the coming year, along with a downward adjustment for next quarter.

On February 5, Evercore ISI analyst Daniel Markowitz reiterated an In Line rating for Bio-Techne Corporation (NASDAQ:TECH). He also increased the price target from $62 to $68, resulting in more than 18% upside potential at the current level.

Markowitz reflected on the company’s fourth quarter guidance, which suggests a light market recovery. He believes that the FY27 organic growth projections for the company appear promising for investors.

Bio-Techne Corporation (NASDAQ:TECH) develops and markets life sciences instruments, reagents, precision diagnostics, and related services. The company offers these for clinical research, diagnostics, gene therapy, and bioprocessing markets. Its product portfolio includes antibodies, immunoassay kits, automated protein analysis systems, hematology, and molecular diagnostic kits.

While we acknowledge the potential of TECH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. Follow Insider Monkey on Google News.